MediWound Ltd.
MDWD · XNASCIK 1593984fmd_1EYEH6SPYXWZTYRVYD0VB4Q6NYManufacturing · Medicinal Chemicals & Botanical ProductsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 20 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 2 | 2 | 3 | 32 | 22 | 24 | 26 | 19 | 20 | 17 |
| Cost of revenue | 2 | 2 | 2 | 12 | 14 | 15 | 13 | 15 | 18 | 14 |
| Gross profit | (1) | 1 | 1 | 20 | 8 | 9 | 13 | 4 | 3 | 3 |
| Research and development | 7 | 5 | 4 | 5 | 8 | 10 | 10 | 7 | 9 | 14 |
| Selling, general and administrative | 4 | 4 | 4 | 5 | 5 | 6 | 7 | 7 | 8 | 8 |
| Operating income | (20) | (14) | (4) | 4 | (9) | (11) | (8) | (15) | (19) | (25) |
| Interest expense | 1 | 1 | 2 | 3 | 1 | 2 | 12 | 2 | 13 | 2 |
| Income before taxes | – | – | – | 2 | (9) | (14) | (20) | (7) | (30) | (24) |
| Income tax expense | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (19) | (15) | (6) | 2 | (9) | (14) | (20) | (7) | (30) | (24) |
| Net income | (19) | (22) | (1) | 5 | (9) | (14) | (20) | (7) | (30) | (24) |